menu ☰
menu ˟

EyePoint launches Dexycu in US

13 Mar 2019
EyePoint Pharmaceuticals has commercially launched Dexycu in the U.S. for the treatment of postoperative inflammation.Dexycu (dexamethasone intraocular suspension 9%) is administered at the end of cataract surgery and is the first FDA-approved intrao...

Click here to view the full article which appeared in Opthalmology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.